A Research Guide for
Lupus (SLE)

• Systemic lupus erythematosus (SLE): The most common and most serious form. Can affect any organ. This is the main focus of this guide.
• Cutaneous lupus: Affects only the skin. Includes discoid lupus (thick, scarring patches), subacute cutaneous lupus (photosensitive rashes), and acute cutaneous lupus (the classic butterfly rash). Some patients with cutaneous lupus later develop SLE.
• Drug-induced lupus: Caused by certain medications (hydralazine, procainamide, isoniazid, and others). Usually resolves when the drug is stopped.
• Neonatal lupus: A rare condition in newborns of mothers with anti-Ro/SSA or anti-La/SSB antibodies. Usually temporary, but can rarely cause permanent congenital heart block.

• Fatigue: The most common symptom, reported by 80–90% of patients. Often severe and disproportionate to other findings.
• Joint pain and swelling: Affects most patients, often in the hands, wrists, and knees. Unlike rheumatoid arthritis, lupus arthritis usually does not cause permanent joint destruction.
• Butterfly (malar) rash: A flat or slightly raised rash across the cheeks and bridge of the nose, sparing the nasolabial folds. Classic but not present in every patient.
• Photosensitivity: Unusual sensitivity to sunlight, causing rashes or flares after UV exposure.
• Mouth or nose ulcers: Often painless and may go unnoticed.
• Hair loss (alopecia): Can be diffuse or patchy.
• Raynaud’s phenomenon: Fingers or toes turn white or blue in cold or stress.
• Unexplained fevers, weight loss, or swollen lymph nodes

The 2019 EULAR/ACR criteria use a points-based system. The entry requirement is a positive ANA (at a titer of 1:80 or higher). Once this is met, points are assigned across clinical and immunological domains:

• Clinical domains: Constitutional (fever), hematologic (low blood counts), neuropsychiatric (seizures, psychosis), mucocutaneous (rash, oral ulcers, hair loss), serosal (pleurisy, pericarditis), musculoskeletal (joint inflammation), renal (proteinuria, nephritis on biopsy)
• Immunological domains: Antiphospholipid antibodies, complement proteins (low C3, C4), specific antibodies (anti-dsDNA, anti-Smith)

A score of 10 or more points classifies a patient as having SLE. The highest-scoring item in each domain is counted. Lupus nephritis confirmed on biopsy alone scores 10 points — enough for classification by itself.

• ANA (antinuclear antibody): The screening test. Positive in nearly all lupus patients but also in many healthy people and other autoimmune conditions. A positive ANA starts the workup; it does not confirm lupus.
• Anti-dsDNA (anti-double-stranded DNA): Highly specific for lupus. Levels often rise during flares, especially kidney flares. Used for both diagnosis and monitoring.
• Anti-Smith (anti-Sm): Very specific for lupus (almost never positive in other diseases). Helpful for confirming diagnosis but does not correlate well with disease activity.
• Anti-Ro/SSA and anti-La/SSB: Associated with photosensitivity, dry eyes/mouth (Sjögren’s overlap), subacute cutaneous lupus, and neonatal lupus risk. Anti-Ro is especially important for pregnancy planning.
• Antiphospholipid antibodies: Anti-cardiolipin, anti-beta2-glycoprotein I, and lupus anticoagulant. Present in 30–40% of lupus patients. Increase the risk of blood clots, pregnancy complications, and stroke.

Complement proteins (C3 and C4) are part of the immune system. In lupus, they are consumed during active disease, so low levels suggest a flare. Your doctor will track complement levels along with anti-dsDNA as part of routine monitoring.

• Low C3 and/or C4: Suggests active lupus, especially active nephritis.
• Falling complement + rising anti-dsDNA: A common pattern before a lupus flare — sometimes detectable weeks before symptoms appear.

• Complete blood count (CBC): May show low white blood cells (leukopenia), low platelets (thrombocytopenia), or anemia — all common in lupus.
• Kidney function: Creatinine, BUN, and urine protein-to-creatinine ratio (uPCR) or 24-hour urine protein. Essential for detecting lupus nephritis.
• Urinalysis: Red blood cells or protein in the urine may indicate kidney involvement.
• ESR and CRP: Inflammatory markers. ESR is often elevated in active lupus. CRP is less reliably elevated in lupus flares (a markedly elevated CRP may suggest infection rather than lupus flare).
• Kidney biopsy: The gold standard for diagnosing and classifying lupus nephritis (by ISN/RPS class). Guides treatment intensity.

The recommended dose is no more than 5 mg per kilogram of actual body weight per day. For most adults, this is 200–400 mg daily. Proper dosing minimizes the small risk of retinal toxicity (damage to the back of the eye).

The American Academy of Ophthalmology (AAO) updated its screening guidelines in 2025:

• Baseline eye exam: Within the first few months of starting hydroxychloroquine.
• Annual screening after 5 years of use (earlier if higher risk: kidney disease, higher doses, tamoxifen use).
• Primary screening tests: Macular OCT (optical coherence tomography) and wide-pattern fundus autofluorescence (FAF).
• Risk: Less than 2% after 10 years of use; up to 8.6% after 15 years. The risk is cumulative and dose-dependent.
• Different patterns in different populations: Parafoveal toxicity is more common in people of European descent; pericentral toxicity is more common in people of East Asian descent. Screening tests should look for both patterns.

If retinal toxicity is detected early, stopping the drug usually prevents further progression. This is why consistent screening matters.

• Gastrointestinal: Nausea, stomach cramps (often improve with time; taking with food helps).
• Skin: Skin darkening (hyperpigmentation), especially in darker skin tones.
• Retinal toxicity: The most serious long-term risk, managed by proper dosing and regular eye screening.
• Rare: Muscle weakness (myopathy), heart rhythm issues (cardiomyopathy — extremely rare at standard doses).

Tip: It takes 2–3 months for hydroxychloroquine to reach full effect. Do not expect immediate results. Stick with it.

• Flare control: Higher doses (0.5–1 mg/kg/day prednisone) for weeks, then taper.
• IV pulse therapy: Methylprednisolone 500–1000 mg IV for 3 days for severe flares (nephritis, cerebritis). This allows faster reduction of oral doses.
• Low-dose maintenance: Some patients need a small dose (5–7.5 mg prednisone) to maintain control. The goal is always to get below 5 mg or off entirely.
• Steroid-sparing agents: Immunosuppressive drugs (azathioprine, mycophenolate, methotrexate) and biologic therapies (anifrolumab, belimumab) are added specifically to allow steroid reduction.

• Bone protection: Calcium, vitamin D, and sometimes bisphosphonates if on prolonged steroids. DEXA bone density scan at baseline and periodically.
• Blood sugar monitoring: Steroids raise blood glucose. If you have diabetes risk, monitor closely.
• Infection prevention: Higher steroid doses increase infection risk. Report fevers or unusual symptoms promptly. Ensure vaccinations are up to date (before starting immunosuppression when possible).
• Eye exams: Monitor for cataracts and glaucoma.
• Mental health: Steroids can cause insomnia, mood swings, anxiety, or depression. Tell your doctor about mood changes.

• Mycophenolate mofetil (CellCept) / mycophenolic acid (Myfortic): Often first-line for lupus nephritis and used for moderate-to-severe non-renal lupus. Effective and generally well tolerated. Must not be used during pregnancy.
• Azathioprine (Imuran): A well-established option for maintenance therapy in mild-to-moderate lupus. One of the few immunosuppressants safe during pregnancy.
• Methotrexate: Particularly effective for lupus arthritis and skin involvement. Taken weekly. Must not be used during pregnancy.
• Cyclophosphamide (Cytoxan): Reserved for severe lupus, especially severe nephritis or life-threatening organ involvement. Given as IV pulses. Carries risks of infections, infertility, and bladder toxicity. Used for induction (initial treatment) and then switched to a safer maintenance drug.
• Tacrolimus / cyclosporine: Calcineurin inhibitors sometimes used for nephritis, especially when mycophenolate is not tolerated or not effective.

• Sunscreen: Broad-spectrum SPF 50+ applied daily, even on cloudy days and indoors near windows. Reapply every 2 hours when outdoors.
• Protective clothing: Wide-brimmed hats, long sleeves with UPF-rated fabric, sunglasses.
• Avoid peak UV: 10 a.m. to 4 p.m. when possible.
• Indoor UV sources: Fluorescent lighting and unfiltered windows can trigger flares in highly photosensitive patients.

• Exercise: Regular, moderate physical activity reduces fatigue, improves cardiovascular health, strengthens bones, and helps with mood. Swimming, walking, and yoga are especially well suited.
• Smoking cessation: Smoking worsens lupus activity, reduces hydroxychloroquine effectiveness, and dramatically increases cardiovascular risk. Quitting is one of the most impactful things a lupus patient can do.
• Vitamin D: Many lupus patients are vitamin D deficient (partly from sun avoidance). Supplementation is commonly recommended.
• Vaccinations: Inactivated vaccines are safe and recommended for lupus patients. Live vaccines (like shingrix live, MMR, yellow fever) require careful timing relative to immunosuppression. COVID-19, flu, and pneumonia vaccines are especially important.
• Stress management: Mindfulness, counseling, adequate sleep, and pacing activities can help manage the fatigue-stress-flare cycle.

Up to 80% of lupus patients show elevated type I interferon gene activity. Anifrolumab blocks the receptor (IFNAR1) that interferon signals through, reducing this inflammation.

• TULIP-1 and TULIP-2 trials: Showed significant improvement in disease activity and allowed greater steroid reduction compared to placebo.
• 4-year long-term data: 30.3% of patients achieved remission (DORIS criteria) versus 18.3% with standard therapy alone. Sustained responses improved over time.
• Subcutaneous autoinjector (April 2026): An at-home self-injection option (the SAPHNELO Pen, 120 mg once weekly) was FDA-approved, based on the TULIP-SC trial. Previously only available as IV infusion (300 mg every 4 weeks) at infusion centers.

Important limitation: Anifrolumab is not indicated for severe active lupus nephritis or active CNS lupus.

• Most common: Upper respiratory infections, herpes zoster (shingles), bronchitis.
• Herpes zoster risk: Higher than with standard therapy. Shingles vaccination (Shingrix, the recombinant vaccine) is recommended before starting if possible.
• Infusion reactions: Can occur with IV administration. Premedication may be used.
• Administration: IV infusion (300 mg) every 4 weeks at a clinic, or subcutaneous self-injection (120 mg) once weekly at home (with the SAPHNELO Pen autoinjector).

• Adult SLE: FDA-approved 2011 (BLISS-52, BLISS-76 trials).
• Pediatric SLE (age 5+): FDA-approved 2019.
• Adult lupus nephritis: FDA-approved 2020 (BLISS-LN trial).
• Pediatric lupus nephritis autoinjector (age 5+): FDA-approved June 2025 — the first at-home treatment option for pediatric lupus nephritis.

Belimumab reduces flares, decreases steroid requirements, and when added to standard lupus nephritis therapy, improves kidney outcomes.

• IV infusion: Once monthly at a clinic (after initial loading doses at weeks 0, 2, and 4).
• Subcutaneous injection: Weekly self-injection at home using a prefilled syringe or autoinjector.
• Side effects: Generally well tolerated. Includes infections, nausea, diarrhea. Rare reports of depression and suicidal ideation require monitoring.

• Anifrolumab is particularly effective for skin and joint manifestations and works best in patients with high interferon gene signature. Not indicated for severe nephritis or CNS lupus.
• Belimumab has the broadest approval range — including lupus nephritis in adults and children. More data on long-term safety (available since 2011).
• Combination: There is growing interest in using both together, though this is not yet standard practice.
• Interferon gene signature testing: Some centers test for type I interferon activity to guide biologic choice. A high interferon signature favors anifrolumab; low or negative may favor belimumab.

Your rheumatologist will consider which organs are affected, your antibody profile, prior treatment responses, and practical factors (IV vs. home injection preference) when recommending a biologic.

• Urine tests: Protein in the urine (proteinuria) and red blood cells or casts in the urine are warning signs.
• Blood tests: Rising creatinine (reduced kidney function), low complement levels, and rising anti-dsDNA antibodies.
• Kidney biopsy: The definitive test. A small tissue sample is examined under the microscope to determine the ISN/RPS class (I through VI). Classes III (focal) and IV (diffuse) are the most common proliferative forms requiring aggressive treatment. Class V (membranous) may present primarily with heavy proteinuria.

The biopsy class determines the treatment approach. Treatment decisions should not be based solely on blood or urine tests without biopsy confirmation in most cases.

• Foamy or frothy urine (from protein)
• Swelling in the legs, ankles, feet, or around the eyes (edema)
• Blood in the urine (may not be visible — microscopic hematuria)
• High blood pressure
• Decreased urine output
• Unexplained weight gain from fluid retention

Many patients have no symptoms at all until nephritis is advanced. Do not wait for symptoms — rely on regular lab monitoring.

The goal is to stop active inflammation quickly. Standard induction options include:

• Mycophenolate mofetil (MMF) with corticosteroids — often preferred for initial treatment, especially for Class III/IV nephritis.
• Low-dose cyclophosphamide (Euro-Lupus protocol) with corticosteroids — an alternative, especially for severe or rapidly progressive nephritis.
• Either regimen + an approved add-on therapy (belimumab, voclosporin, or obinutuzumab) for improved response rates.

Hydroxychloroquine should be continued throughout (it improves kidney outcomes independently).

Three drugs are now specifically FDA-approved for lupus nephritis, all used in addition to standard immunosuppressive therapy:

• Belimumab (Benlysta) — approved 2020: Added to standard induction and maintenance. The BLISS-LN trial showed improved kidney response and reduced the risk of kidney-related events.
• Voclosporin (Lupkynis) — approved 2021: An oral calcineurin inhibitor designed specifically for lupus nephritis. Combined with mycophenolate. The AURORA trial showed significantly higher complete renal response rates. Taken as twice-daily oral capsules. Requires blood pressure monitoring.
• Obinutuzumab (Gazyva) — approved October 20, 2025: The newest option. A type II anti-CD20 antibody (glycoengineered for enhanced B-cell depletion). The REGENCY Phase III trial showed 46.4% achieved complete renal response versus 33.1% with placebo. Given as IV infusion. Carries risks of infusion reactions, infections, and hepatitis B reactivation.

After successful induction, maintenance therapy continues for at least 3–5 years (some patients need indefinite treatment):

• Mycophenolate (usually at a lower dose than induction) is the most common maintenance agent.
• Azathioprine is an alternative, especially if pregnancy is planned.
• Continue hydroxychloroquine indefinitely.
• Taper steroids aggressively — ideally to below 5 mg prednisone or off entirely within 6–12 months.
• Blood pressure control is critical. ACE inhibitors or ARBs are preferred because they also reduce proteinuria.

• Increasing fatigue beyond your usual baseline
• New or worsening joint pain and swelling
• New rash or worsening of existing rash, especially after sun exposure
• Mouth sores
• Low-grade fevers
• New hair loss
• Swollen ankles or puffy eyes (possible kidney flare)
• Chest pain with deep breathing (possible pleurisy or pericarditis)

Many patients learn to recognize their own personal flare warning signs over time. Keeping a symptom diary can help identify patterns and triggers.

• Disease remission for at least 6 months before conception. Active lupus at conception dramatically increases the risk of flares, preeclampsia, preterm birth, and fetal loss.
• Medication review: Some lupus medications are safe in pregnancy; others must be stopped months in advance:
  • Safe: Hydroxychloroquine (must continue — reduces flare risk by 50%), azathioprine, tacrolimus, low-dose prednisone
  • Must stop before conception: Mycophenolate (teratogenic — stop at least 6 weeks before), methotrexate (stop at least 3 months before), cyclophosphamide, leflunomide
• Antibody testing: Anti-Ro/SSA antibodies (risk of neonatal lupus and congenital heart block — fetal echocardiography from 16 to 26 weeks is recommended). Antiphospholipid antibodies (risk of blood clots and pregnancy loss — prophylactic blood thinners may be needed).
• Kidney function check: Active lupus nephritis must be fully treated and stable before pregnancy.

• Continue hydroxychloroquine throughout.
• Low-dose aspirin starting at 12 weeks for all lupus pregnancies (reduces preeclampsia risk).
• Close monitoring: Regular rheumatology and high-risk obstetric visits, frequent lab work (complement, anti-dsDNA, kidney function, urine protein).
• Distinguishing lupus flare from preeclampsia: Both can cause high blood pressure and proteinuria. Active complement consumption, rising anti-dsDNA, and active urine sediment suggest a lupus flare. Your medical team will help differentiate these.
• Antiphospholipid syndrome: If present, prophylactic heparin or low-molecular-weight heparin plus low-dose aspirin throughout pregnancy.

• Diagnosis: Requires the combination of a blood clotting event or pregnancy complication AND persistent positive antiphospholipid antibodies (tested positive on two occasions at least 12 weeks apart).
• Primary prevention: Lupus patients with antiphospholipid antibodies but no prior clot may be given low-dose aspirin to reduce risk.
• After a clot: Lifelong anticoagulation with warfarin is typically required. Direct oral anticoagulants (DOACs like rivaroxaban) are generally not recommended for APS — a major trial showed they were less effective than warfarin.
• In pregnancy: Heparin/LMWH plus low-dose aspirin.
• Catastrophic APS: A rare, life-threatening variant with rapid multi-organ clotting. Requires emergency treatment in an ICU.

• Fatigue: Affects 80–90% of patients. Multifactorial — caused by inflammation, poor sleep, depression, anemia, thyroid dysfunction, and medications. Regular exercise is the most consistently effective intervention. Optimizing sleep hygiene, treating anemia, and screening for thyroid disease help. Pace activities and use energy conservation strategies.
• Depression and anxiety: Common in chronic illness and especially in lupus (which can directly affect the brain). Should be actively screened for and treated. Counseling, cognitive behavioral therapy, and medication (SSRIs are generally safe with lupus) are all options.
• Cognitive dysfunction (“lupus fog”): Memory problems, difficulty concentrating, word-finding difficulties. Can be caused by active CNS lupus, antiphospholipid antibodies, medication effects, or coexisting depression and fatigue. Report cognitive changes to your doctor.
• Neuropsychiatric lupus (NPSLE): Lupus can directly attack the nervous system, causing seizures, psychosis, stroke, or severe cognitive impairment. This is a medical emergency requiring urgent evaluation and treatment.

• The risk: Lupus causes chronic inflammation that accelerates atherosclerosis. Steroids worsen lipids, blood sugar, and blood pressure. Antiphospholipid antibodies increase clotting. Kidney disease adds further risk.
• What you can do:
  • Control blood pressure (target below 130/80 for most lupus patients)
  • Monitor and treat high cholesterol
  • Manage blood sugar (especially if on steroids)
  • Do not smoke
  • Exercise regularly
  • Maintain a healthy weight
  • Take hydroxychloroquine (it improves lipid profiles independently)
  • Minimize steroid exposure
• Damage index: Over time, both active lupus and medication side effects can cause cumulative organ damage (measured by the SDI — SLICC Damage Index). Every year of uncontrolled disease or unnecessary steroid exposure adds damage that cannot be reversed. This is why the treat-to-target approach — aiming for remission or low disease activity — is so critical.

Chimeric antigen receptor T-cell (CAR-T) therapy, borrowed from cancer treatment, has produced dramatic responses in patients with severe, treatment-resistant lupus. The approach involves collecting a patient’s T cells, engineering them to target B cells (using anti-CD19 or anti-BCMA markers), and reinfusing them to deplete the B cells driving autoimmunity.

• A review presented at ACR 2025 summarized 145 patients across 16 studies: most achieved deep remission, and many were able to stop all immunosuppressive medications.
• The RESET-SLE trial with rese-cel (resecabtagene autoleucel) showed rapid B-cell depletion and reconstitution within 8–20 weeks.
• CAR-T is still investigational for lupus and is not FDA-approved. It is available only through clinical trials and carries significant risks including infections and cytokine release syndrome.
• Over 100 clinical trials for CAR-T in autoimmune diseases are underway worldwide.

This is an exciting frontier, but it remains years away from routine clinical use.

• Dapirolizumab pegol (anti-CD40L): Blocks the CD40–CD40L “co-stimulation” signal that drives B-cell and T-cell activation. In the Phase 3 PHOENYCS GO trial (321 patients), adding dapirolizumab pegol to standard care improved overall disease activity at 48 weeks (BICLA response 49.5% vs 34.6% on placebo) and allowed lower steroid doses, with no blood-clot safety signal. Results were published in The Lancet (2025); a second Phase 3 trial (PHOENYCS FLY) is underway.
• Iptacopan (Fabhalta): An oral drug that blocks part of the complement immune system. It is already approved for several other conditions and is now in a Phase 2 trial as an add-on treatment for active lupus nephritis (lupus kidney disease).
• Deucravacitinib (TYK2 inhibitor): An oral drug that selectively blocks TYK2, a signaling enzyme involved in interferon, IL-12, and IL-23 pathways. Already approved for psoriasis. Four-year data in moderate-to-severe SLE showed consistent safety and durable efficacy. Phase 3 trials (POETYK SLE-1 and SLE-2) are ongoing with results expected soon.
• Iberdomide: A cereblon modulator (CELMoD) that degrades transcription factors critical for autoimmune B and T cell function. In Phase 3 trials.
• Cenerimod: An S1P1 receptor modulator that reduces circulating lymphocytes. Phase 3 CARE trial is ongoing.
• Litifilimab: Targets plasmacytoid dendritic cells, a key source of interferon in lupus.
• Atacicept and telitacicept: Dual BAFF/APRIL blockers that target B cell survival more broadly than belimumab. Telitacicept is approved in China for SLE.

• Black/African American women with lupus die an average of up to 13 years earlier than White women with the same disease.
• Death rates in Hispanic and Asian women with lupus are 4–6 times higher than expected.
• Minority patients have higher rates of lupus nephritis and progression to kidney failure.
• Social determinants — healthcare access, insurance status, income, education, food security, and neighborhood safety — drive much of the disparity, alongside biological factors.
• The Lupus Foundation of America published 33 high-impact solutions for health equity in August 2025.
• The 2025 ACR guidelines specifically address equity considerations in treatment recommendations.
• Clinical trials have historically underrepresented minority patients, but recent trials (EMBRACE for belimumab in Black patients) are working to change this.

If you are from a community disproportionately affected by lupus, know that your experience is valid, the disparities are real, and advocacy for equitable care matters. Seek out lupus support organizations that center diverse communities.

• United States (FDA) — Hydroxychloroquine, belimumab (SLE + LN, adults + pediatric), anifrolumab (SLE), voclosporin (LN), and obinutuzumab (LN, approved October 2025) are all FDA-approved. Anifrolumab subcutaneous autoinjector was approved in 2026.
• European Union (EMA) — Belimumab and anifrolumab are EMA-approved for SLE. Voclosporin is EMA-approved for lupus nephritis. Obinutuzumab EMA submission for LN is expected. Rituximab is widely used off-label for refractory SLE across Europe.
• United Kingdom (NICE/MHRA) — Belimumab and anifrolumab are NICE-approved. Rituximab is commonly used off-label through the NHS for refractory SLE. Voclosporin is under NICE review.
• Japan (PMDA) — Belimumab is PMDA-approved. Hydroxychloroquine was approved for SLE in Japan in 2015 (much later than other countries). Anifrolumab has been approved. Multitarget regimens with tacrolimus are widely used for lupus nephritis in Japan.
• Canada (Health Canada) — Belimumab and anifrolumab are approved. Voclosporin (developed by the Canadian company Aurinia Pharmaceuticals) is approved for LN.
• Australia (TGA/PBAC) — Belimumab and anifrolumab are PBS-listed. Access to biologics may require specialist authorization.
• China (NMPA) — Belimumab is approved. Telitacicept (a dual BAFF/APRIL blocker) is approved for SLE in China but not yet in the US or EU.

Several treatments are available in some countries but not yet approved in the United States:

• Telitacicept: A dual BAFF/APRIL blocker approved for SLE in China. It targets B-cell survival more broadly than belimumab. Global Phase 3 trials are ongoing.
• Rituximab for SLE: While not FDA-approved specifically for SLE, rituximab is used off-label worldwide (especially in the UK and Europe) for refractory lupus. Obinutuzumab (a newer anti-CD20 antibody) is now FDA-approved for lupus nephritis.

If you are traveling internationally or considering treatment abroad, always coordinate with your home rheumatologist to ensure continuity of care.

• Rituximab (for general SLE) — Despite widespread off-label use, rituximab failed to meet primary endpoints in two major Phase 3 trials for non-renal SLE: EXPLORER (2010) and LUNAR (lupus nephritis, 2012). It remains used off-label for refractory cases, but it was never FDA-approved for SLE. Obinutuzumab, a next-generation anti-CD20, succeeded where rituximab did not (REGENCY trial, 2025). FAILED Phase 3
• Epratuzumab (anti-CD22) — This B-cell-targeting antibody failed in two Phase 3 trials (EMBODY-1 and EMBODY-2, 2015). Despite early promise, it showed no significant benefit over placebo for moderate-to-severe SLE. Development was discontinued. FAILED
• Tabalumab (anti-BAFF) — A monoclonal antibody similar to belimumab that targeted BAFF. Failed in the ILLUMINATE-1 and ILLUMINATE-2 Phase 3 trials (2014–2015). It did not demonstrate consistent efficacy. Development was discontinued. FAILED
• Abatacept (CTLA-4-Ig) for general SLE — Effective in rheumatoid arthritis, but abatacept failed to meet primary endpoints in Phase 3 SLE trials. Some benefit was seen in lupus nephritis (ACCESS study), but results were insufficient for FDA approval in lupus. FAILED
• Baricitinib and other JAK1/2/3 inhibitors — While JAK inhibitors showed some early signals in SLE, safety concerns (cardiovascular events, malignancy, thrombosis identified in RA studies) have limited enthusiasm for broad-spectrum JAK inhibitors in lupus. Selective TYK2 inhibition (deucravacitinib) is being pursued instead as a potentially safer approach. DE-ADOPTED
• Oral DHEA (dehydroepiandrosterone / prasterone) — Once explored as an adjunctive treatment for SLE fatigue and mild disease. Clinical trials showed marginal benefit at best. It is not recommended in current guidelines. DE-ADOPTED
• High-dose intravenous cyclophosphamide (NIH protocol) — The original NIH protocol used high-dose monthly cyclophosphamide for 6 months followed by quarterly dosing for 2 years. While effective, it caused significant toxicity (infections, infertility, bladder cancer risk). The lower-dose Euro-Lupus protocol has largely replaced it as the standard cyclophosphamide regimen, with comparable efficacy and far fewer side effects. DE-ADOPTED

• Lupus Foundation of America (LFA): lupus.org — Education, support groups, research funding, advocacy. The largest lupus organization in the US.
• Lupus Research Alliance: lupusresearch.org — Funds lupus research. Provides clinical trial finder and educational materials.
• Alliance for Lupus Research: Merged with Lupus Research Alliance. Combined resources available at lupusresearch.org.
• Lupus and Allied Diseases Association: advocacy and support for lupus and overlapping conditions.
• ClinicalTrials.gov: Search “systemic lupus erythematosus” to find active clinical trials in your area.

• LFA local chapters: In-person and virtual support groups across the US.
• MyLupusTeam: Online social network for people living with lupus.
• Inspire lupus communities: Online discussion boards.
• Social media: #LupusWarrior, #LupusAwareness communities on Instagram and Facebook can provide peer connection (always verify medical information with your care team).

• University of Utah Division of Rheumatology: Academic rheumatology program with lupus expertise. Connected to Huntsman Cancer Institute for overlapping conditions.
• Intermountain Health Rheumatology: Multiple locations along the Wasatch Front with lupus-experienced rheumatologists.
• Primary Children’s Hospital Pediatric Rheumatology: For childhood-onset lupus. Part of the University of Utah system.
• LFA Utah Chapter: Local support groups, educational events, and lupus walks.
• University of Utah Kidney Transplant Program: For patients who progress to end-stage renal disease from lupus nephritis.
• Utah Health & Human Services: Assistance programs for medication costs, insurance navigation, and disability services.

• 2025 ACR Guideline for the Treatment of Systemic Lupus Erythematosus
• 2023 EULAR SLE Management Recommendations (Fanouriakis et al., Ann Rheum Dis 2024)
• EULAR 2025 Lupus Nephritis Update (4 principles, 13 recommendations)
• 2019 EULAR/ACR SLE Classification Criteria (Aringer et al., Arthritis Rheumatol 2019)
• KDIGO 2024 Lupus Nephritis Guidance
• AAO 2025 Revision: Screening for Hydroxychloroquine Retinopathy
• TULIP-1, TULIP-2, TULIP-SC, TULIP LTE (anifrolumab trials)
• BLISS-52, BLISS-76, BLISS-LN, EMBRACE (belimumab trials)
• AURORA Phase 3 (voclosporin)
• REGENCY Phase III (obinutuzumab)
• NOBILITY Phase II (obinutuzumab)
• PAISLEY-SLE Phase 2, POETYK SLE Phase 3 (deucravacitinib)
• Mackensen et al., Nature Medicine 2022; Muller et al., NEJM 2024 (CAR-T in SLE)
• ACR 2025 CAR-T SLE review (145 patients, 16 studies)
• Lupus Foundation of America 2025 health disparities report

• SLE (systemic lupus erythematosus) — A chronic autoimmune disease in which the immune system mistakenly attacks healthy tissues throughout the body, potentially affecting the skin, joints, kidneys, brain, and other organs.
• ANA (antinuclear antibody) — A blood test that detects antibodies directed against the nucleus of your own cells. A positive ANA is found in nearly all people with lupus, though it can also occur in other conditions.
• Anti-dsDNA — An antibody that targets double-stranded DNA, found mainly in lupus. Rising levels often signal increased disease activity, especially kidney involvement.
• Complement (C3/C4) — Proteins in the blood that help the immune system fight infections. In lupus, low C3 or C4 levels suggest the immune system is actively consuming these proteins during a flare.
• Hydroxychloroquine (HCQ) — An antimalarial medication that is the cornerstone of lupus treatment. It reduces flares, protects the kidneys, lowers blood clot risk, and improves long-term survival.
• Belimumab (Benlysta) — A biologic medication given by injection or infusion that blocks a protein called BLyS, which fuels the overactive immune cells in lupus. It is approved for active SLE and lupus nephritis.
• Anifrolumab (Saphnelo) — A biologic medication given by infusion that blocks type I interferon, a key driver of inflammation in many lupus patients. It is approved for moderate-to-severe SLE.
• Voclosporin (Lupkynis) — An oral calcineurin inhibitor approved specifically for lupus nephritis. It suppresses the immune attack on the kidneys and is taken alongside mycophenolate and low-dose steroids.
• Obinutuzumab (Gazyva) — A biologic infusion that depletes B cells (the immune cells that produce harmful antibodies). It was approved in October 2025 for lupus nephritis based on the REGENCY trial.
• Lupus nephritis — Inflammation of the kidneys caused by lupus, occurring in roughly half of SLE patients. It is detected through urine tests and kidney biopsy and requires prompt, aggressive treatment to preserve kidney function.
• ISN/RPS class — A classification system (Classes I through VI) used to grade the severity and type of kidney damage seen on a lupus nephritis biopsy. Classes III and IV are the most serious and require the strongest immunosuppression.
• SLEDAI — The SLE Disease Activity Index, a scoring tool doctors use to measure how active your lupus is at a given time. Higher scores mean more active disease.
• APS (antiphospholipid syndrome) — A clotting disorder that often accompanies lupus, caused by antibodies that make the blood more likely to form dangerous clots. It can affect veins, arteries, and pregnancy outcomes.
• Flare — A period when lupus symptoms suddenly worsen or new symptoms appear. Flares can range from mild (joint pain, rash) to severe (kidney or brain involvement) and are followed by periods of remission.
• Steroid-sparing — A treatment strategy that uses other medications (biologics, immunosuppressants) to control lupus so that steroid (prednisone) doses can be reduced or eliminated, avoiding long-term steroid side effects.
• CAR-T — Chimeric antigen receptor T-cell therapy, a cutting-edge treatment in which a patient's own immune cells are engineered in a laboratory to target and destroy the B cells driving lupus. It is currently used only in severe, treatment-resistant cases.
• Retinal screening — Regular eye examinations (typically with OCT imaging) to check for early signs of retinal damage from long-term hydroxychloroquine use. Current guidelines recommend screening within the first year and then annually after five years of use.